A Safety and Efficacy Study of Domvanalimab + Zimberelimab Combination Therapy in Participants With Advanced Upper Gastrointestinal Tract Malignancies

Overview

Información sobre este estudio

This Phase 2, open-label, parallel, 3-cohort, multicenter study will evaluate the safety and efficacy of various combinations of the anti-T-cell immunoglobulin and ITM domain (TIGIT) monoclonal antibody domvanalimab, the anti-programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy in the first--line setting, and of various combinations of domvanalimab, zimberelimab, the cluster of differentiation 73 (CD73) inhibitor quemliclustat, and chemotherapy in the second-line (2L) or greater setting in participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Key Inclusion Criteria:

- Participants with histologically confirmed diagnosis of locally advanced unresectable
or metastatic gastric, GEJ, or esophageal adenocarcinoma with life expectancy ≥3
months as assessed by the Investigator

- Eastern cooperative oncology group (ECOG) Performance Score of 0-1

- At least one measurable target lesion per RECIST v1.1.

- Adequate organ and marrow function

- Able to provide an archival tumor sample that is representative of the cancer under
investigation and suitable for central PD-L1 testing

Key Exclusion Criteria:

- Participants with underlying medical conditions that, in the Investigator's or
Sponsor's opinion, will make the administration of investigational products hazardous

- Only for Cohort A: Known Human Epidermal Growth Factor Receptor 2 (HER-2) positive
tumor

- Known untreated, symptomatic, or actively progressing central nervous system (brain)
metastases. Participants with leptomeningeal metastases are excluded from enrollment.

- Discontinued use of prior immune checkpoint therapy due to immune related adverse
events; received prior treatment with an anti-TIGIT monoclonal antibody.

- History of trauma or major surgery within 28 days prior to enrollment.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/10/2024. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Jason Starr, D.O.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Mohamad Bassam Sonbol, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available

Información adicional de contacto

Formulario de contacto para ensayos sobre cáncer

Teléfono: 855-776-0015 (toll-free)

Preguntas de estudios clínicos para pacientes internacionales